Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 127.50 125.00 130.00 127.50 127.50 127.50 52,225 07:49:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 72

Reneuron Share Discussion Threads

Showing 8026 to 8048 of 8325 messages
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
DateSubjectAuthorDiscuss
09/11/2020
10:28
I'm expecting a placing here, cash burn was £14m last year & they had £12.6m left at 31st March, so assuming the £1.2m a month burn has continued they'll have around £4m left at present? This would be a classic pre placing bounce, attracting some volume to enable the placing shares to be in the money once issued... Could be wrong, but I've seen it plenty of times before on AIM.
74tom
09/11/2020
10:11
My top-up on the 3rd looks like it may have been well timed. I wonder what is cooking? If anything?
lauders
09/11/2020
10:11
Worth noting record price was (in new money) £5 back in the day. All blue-sky then, less blue-sky now.
small crow
09/11/2020
10:04
Anyone else smell money?
small crow
09/11/2020
09:31
£1.38 resistance to be tested on the news....
onehanded
09/11/2020
09:12
looking good for news soon.....
onehanded
06/11/2020
16:16
Snow's on the way, I hear :-)
whatno
06/11/2020
16:14
Something big brewing for next week.....
onehanded
06/11/2020
15:51
John Berriman, one of the non-exec directors bought 80,000 @ 225.00p not that long ago. He is nursing a big paper loss but presumably thought they were good value at that price after seeing the early hRPC trial results.
onceaday
06/11/2020
09:42
where do you see staff buying shares?
stewart_25
05/11/2020
14:51
staff buying shares, must be news soon lol. Can't tell you how that news leaked.
onehanded
04/11/2020
09:28
exospike covid 19 in play here. Plus trail result due. Watching...
onehanded
03/11/2020
18:15
They are hard to value because of a dependency on the RP trial and exosome research results that are not yet known. From a share price perspective, hard data on either the RP trial or their internal research programs should move the price upwards. I can only see circa £5 being reached if they announce a significant partnering deal. Taking the ex-US jCyte deal and doubling it to take into account US rights would give $500M. That's well in excess of 10x RENE's market cap. How much is the company worth without a deal? I would imagine that the breakup value is at least the current market cap given their IP portfolio and proprietary technology.
onceaday
03/11/2020
17:03
Edison have them as being worth £5.30
philh75
03/11/2020
16:05
I agree - this is somewhat slow burn but ultimately the ph2a extension results are very unlikely to disappoint especially given the increase to two million cells and the procedural enhancements. I also believe we are due an update regarding RENE's internal research programs before the end of the year. As OH has stated, RENE's COVID19 exospike may get traction if the first generation of vaccines provide only limited efficacy.
onceaday
03/11/2020
15:56
I was told by medical science professor that T cells covid response is the next big test to see how the body response to defence / immune response in infection rather than or in addition to normal antibody test being done. I do believe that this is being trailed here, we will see..... worth a punt and add in update of other trails expected soon. Considering another company like this just been bought out, I expect other large pharmaceutical companies eyeing it. Support is building. £1.40p would be a tough nut to crack though. need to keep quiet while small PI build lol.
onehanded
03/11/2020
14:51
Added some shares to the pot today. Just a matter of patience here I hope. The news will hopefully be worth waiting for, whether it is an update on the trials or a new alliance.
lauders
29/10/2020
20:06
It's an interesting point as to what extent Orphan Designation offers protection. As I understand it, if a later treatment demonstrates a much greater benefit (efficacy, cost, etc) than the original orphan treatment then it may still be approved. I also wonder how different hRPCs will compete in the market place. Doctor's generally have the right to determine how they use a drug and often prescribe "off-label". What would happen in a scenario where RENE developed subretinal hRPCs and jCyte developed intravitreal hRPCs? If they were both approved products then a doctor could presumably choose either for off-label use? Any ideas?
whatno
29/10/2020
19:48
I'm sure they will - they've got orphan designation haven't they? - so as I understand it they get 7 years exclusivity automatically for rp. But Vedere/Novartis seem to be casting their net wider - although still in the arena of gene-related sight defects - so I assume they'll find something else they can focus on if rene get their act together. But the world does move on...
supernumerary
29/10/2020
17:24
Looks like a competitor, unless Novartis wants to buy a full house... https://www.fiercebiotech.com/biotech/novartis-drops-150m-stealthy-gene-therapy-startup Novartis sharpens focus on vision-restoring gene therapy with $150M Vedere buyout by Amirah Al Idrus | Oct 29, 2020 2:15am Vedere Bio didn’t stand a chance. The Atlas Venture gene therapy startup was working under the radar and contemplating another venture round when it got an offer it couldn’t refuse: $150 million upfront to become part of Novartis, with another $130 million promised if it hits certain goals. “Even before we came out of stealth mode, there was a lot of inbound interest through the Atlas network and through my own network,” said Cyrus Mozayeni, M.D., CEO of Vedere Bio and an entrepreneur in residence at Atlas Venture. Through the buyout, Novartis gets its hands on a group of preclinical gene therapies designed to restore vision. “We had deep discussions with other parties, but Novartis really stepped away from the pack in terms of their level of interest, not just financially, but in terms of the team they came to the discussion with and the level of sophistication and thought they put into the conversation with us,” he added. The deal follows Eli Lilly's $135 million buyout of Disarm Therapeutics, a preclinical-stage company working on treatments for amyotrophic lateral sclerosis and other neurodegenerative diseases, and comes as biotechs are going public at increasingly earlier stages. Vedere's own preclinical programs aim to treat vision loss caused by the death of photoreceptors, or light-sensing cells in the retina, rather than blindness stemming from damage to the brain or optic nerve. And they’re optogenetic, meaning that they work by delivering the genetic code to express a light-sensing protein in the retina. “When light comes into the eye, it interacts with that light-sensing protein and leads to a neuro-electrical signal through the optic pathway back to the brain, which, hopefully, will recapitulate the sight that has been lost,” Mozayeni said. The hope is not to just slow down or stop vision loss, but to restore vision, making it possible to treat patients at any stage of their disease. The optogenetic approach also means the treatments should work regardless of the genetic mutation that underlies a person’s vision loss. Other genetic treatments, such as Roche’s Luxturna or Editas Medicine's clinical-stage EDIT-101, address specific mutations that cause Leber congenital amaurosis, an inherited form of blindness. [ ... ]
supernumerary
09/10/2020
20:51
The next few months could bring newsflow that may have a significant effect on the share price. It's clear that the phase 2a extension study in RP is underway and if early results are clinically significant then this may be deemed "material" for market reporting purposes. Rene.are also due to report on exosome collaborations "late this year and into next" there could news on CTX partnering outside of China as well as progress by Fosun. The share has drifted down from a high of £3 last year to sub £1 today. Any significant news will command a 30% premium for sure!
onceaday
03/10/2020
17:27
Ummm, could be!
rayrac
02/10/2020
12:31
Starting to wonder if someone's heard something?
small crow
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 10:25:47